Skip to main navigation

Now accepting applications for SPARK™ - Albireo’s Grants in Rare Liver Disease program. Learn more.

Clinical Trials
Partnerships
Media
Careers
Contact

Science & Medicine
Patients & Families
Responsibility
About Us
- Leadership
- Board of Directors
Investors

+

Science & Medicine
Patients & Families
Responsibility
About Us
Investors
Careers
Media
Contact

Press Releases

Year

August 15, 2022

Albireo Reports Q2 2022 Financial Results and Business Update

August 10, 2022

Albireo Appoints New Members to Board of Directors

August 3, 2022

Albireo to Participate in 2022 Wedbush PacGrow Healthcare Conference

August 1, 2022

Albireo to Report Q2 2022 Financial Results on August 15, 2022

July 26, 2022

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2022

The Lancet Gastroenterology & Hepatology Publishes Data from Albireo’s Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC

June 30, 2022

Albireo to Present at the William Blair Biotech Focus Conference 2022

June 24, 2022

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

June 23, 2022

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

June 8, 2022

Albireo to Present New Data at the EASL International Liver Congress™ 2022

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Email Alerts
RSS
Print

Site Map
Privacy Policy
Terms of Use
Cookie Settings
Contact

© 2022 Albireo Pharma, Inc